Articles with "repair deficient" as a keyword



Photo from wikipedia

Effects of CDX2 on prognosis and chemotherapy responsiveness in mismatch repair‐deficient colorectal cancer

Sign Up to like & get
recommendations!
Published in 2018 at "BJS Open"

DOI: 10.1002/bjs5.91

Abstract: Caudal‐related homeobox transcription factor 2 (CDX2) is an intestine‐specific transcription factor implicated in tumour differentiation, proliferation, cell adhesion and migration. Negative CDX2 status (CDX2−) is associated with worse prognosis in colorectal cancer and may identify… read more here.

Keywords: prognosis; colorectal cancer; repair deficient; mismatch repair ... See more keywords
Photo from wikipedia

T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers

Sign Up to like & get
recommendations!
Published in 2018 at "Modern Pathology"

DOI: 10.1038/s41379-018-0172-x

Abstract: Mismatch repair-deficient endometrial cancers have a high somatic mutation burden, suggesting that patients with these tumors may benefit from immunotherapy. Elucidating the immune suppressive mechanisms of mismatch repair-deficient endometrial cancers is fundamental to developing future… read more here.

Keywords: immune; deficient endometrial; repair deficient; mismatch repair ... See more keywords
Photo by ospanali from unsplash

TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers

Sign Up to like & get
recommendations!
Published in 2019 at "Modern Pathology"

DOI: 10.1038/s41379-019-0251-7

Abstract: The checkpoint molecule TIM-3 is a target for emerging immunotherapies and has been identified on a variety of malignancies. Mismatch repair-deficient endometrial carcinomas have demonstrated durable responses to other checkpoint inhibitors due to high neoantigen… read more here.

Keywords: repair deficient; expression; tim; mismatch repair ... See more keywords
Photo by dancristianpaduret from unsplash

CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors

Sign Up to like & get
recommendations!
Published in 2022 at "Oncoimmunology"

DOI: 10.1080/2162402x.2022.2094583

Abstract: ABSTRACT Mismatch repair-deficient (dMMR) tumors show a good response toward immune checkpoint inhibitors (ICI), but developing resistance impairs patients’ outcomes. Here, we compared the therapeutic potential of an α-PD-L1 antibody with the CDK4/6 inhibitor abemaciclib… read more here.

Keywords: mismatch repair; wks wks; repair deficient; treatment ... See more keywords

LAG-3 and GAL-3 in Endometrial Carcinoma: Emerging Candidates for Immunotherapy

Sign Up to like & get
recommendations!
Published in 2020 at "International Journal of Gynecological Pathology"

DOI: 10.1097/pgp.0000000000000608

Abstract: LAG-3 is an immunosuppressive checkpoint molecule expressed on T cells. One of its ligands, GAL-3, can promote the progression of malignancy and has been identified on tumor cells. Both LAG-3 and GAL-3 are the targets… read more here.

Keywords: mismatch repair; repair deficient; lag gal; repair ... See more keywords
Photo from wikipedia

Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer

Sign Up to like & get
recommendations!
Published in 2022 at "Cancer Science"

DOI: 10.1111/cas.15650

Abstract: The phase 3 KEYNOTE‐177 study evaluated pembrolizumab versus chemotherapy with or without bevacizumab or cetuximab in patients with newly diagnosed, microsatellite‐instability‐high (MSI‐H)/mismatch‐repair‐deficient (dMMR) metastatic colorectal cancer (mCRC). Primary endpoints were progression‐free survival (PFS) per RECIST… read more here.

Keywords: microsatellite instability; mismatch repair; instability high; repair deficient ... See more keywords
Photo from wikipedia

Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab

Sign Up to like & get
recommendations!
Published in 2022 at "International Journal of Gynecological Cancer"

DOI: 10.1136/ijgc-2022-003492

Abstract: Objective There is an increase in patient-reported outcome assessments to gain information on new drug candidates from the patient’s perspective. A data gap remains in patient-reported outcome measurements for anti-programmed death 1 (anti-PD-1) therapies in… read more here.

Keywords: endometrial cancer; mismatch repair; patient reported; repair deficient ... See more keywords
Photo from wikipedia

Comparative molecular genomic analyses of a spontaneous rhesus macaque model of mismatch repair-deficient colorectal cancer.

Sign Up to like & get
recommendations!
Published in 2022 at "PLoS genetics"

DOI: 10.1371/journal.pgen.1010163

Abstract: Colorectal cancer (CRC) remains the third most common cancer in the US with 15% of cases displaying Microsatellite Instability (MSI) secondary to Lynch Syndrome (LS) or somatic hypermethylation of the MLH1 promoter. A cohort of… read more here.

Keywords: mismatch repair; cancer; crc; colorectal cancer ... See more keywords
Photo from wikipedia

How history and geography may explain the distribution in the Comorian archipelago of a novel mutation in DNA repair-deficient xeroderma pigmentosum patients

Sign Up to like & get
recommendations!
Published in 2019 at "Genetics and Molecular Biology"

DOI: 10.1590/1678-4685-gmb-2019-0046

Abstract: Abstract Xeroderma pigmentosum (XP) is a rare, genetic, autosomal nucleotide excision repair-deficient disease characterized by sun-sensitivity and early appearance of skin and ocular tumors. Thirty-two black-skinned XP from Comoros, located in the Indian Ocean, were… read more here.

Keywords: mutation; xeroderma pigmentosum; geography may; history geography ... See more keywords
Photo from wikipedia

Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair-Deficient Colorectal Cancer.

Sign Up to like & get
recommendations!
Published in 2023 at "Journal of the National Comprehensive Cancer Network : JNCCN"

DOI: 10.6004/jnccn.2022.7060

Abstract: BACKGROUND Our study aimed to evaluate the efficacy and feasibility of neoadjuvant anti-PD-1 treatment for localized mismatch repair-deficient (dMMR) colorectal cancer (CRC). PATIENTS AND METHODS The study cohort included patients with localized dMMR CRC who… read more here.

Keywords: mismatch repair; localized mismatch; recurrence; repair deficient ... See more keywords